Onyx Therapeutics, Inc.

États‑Unis d’Amérique

 
Quantité totale PI 71
Rang # Quantité totale PI 18 834
Note d'activité PI 1,8/5.0    10
Rang # Activité PI 89 138
Parent Onyx Pharmaceuticals, Inc.

Brevets

Marques

43 0
12 0
16 0
0
 
Dernier brevet 2023 - Immunoglobulin expression levels...
Premier brevet 2005 - Compounds for enzyme inhibition

Derniers inventions, produits et services

2022 Invention Immunoglobulin expression levels as biomarker for proteasome inhibitor response. Methods of trea...
2021 Invention Compounds for proteasome enzyme inhibition. Peptide-based compounds including heteroatom-contain...
2020 Invention Tripeptide epoxy ketone protease inhibitors. Provided herein are tripeptide epoxy ketone protease...
Invention Combination therapy with peptide epoxyketones. The invention provides combination therapy, where...
2019 Invention Compounds for proteasome. Peptide-based compounds including heteroatom-containing, three-membere...
Invention Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment...
2018 Invention Prodrugs of peptide epoxy ketone protease inhibitors. This disclosure features compounds that are...
2017 Invention Combination therapy with peptide epoxyketones. ABSTRACT The invention provides combination therap...
Invention Peptide epoxyketone immunoproteasome inhibitors. Provided herein are tripeptide epoxy ketone prot...
Invention Compounds for enzyme inhibition. Peptide-based compounds including heteroatom-containing, three-m...
2016 Invention Combination therapy with peptide epoxyketones. The invention provides combination therapy, wherei...
Invention Modified release formulations for oprozomib. This disclosure features modified release pharmaceu...
2015 Invention Compunds for enzyme inhibition. Peptide-based compounds including heteroatom-containing, three-m...
Invention Crystalline tripeptide epoxy ketone protease inhibitors. The invention relates to crystalline tri...
Invention Compounds for enzyme inhibition. One aspect of the invention relates to inhibitors that preferent...
2014 Invention Use of peptide epoxyketones for metastasis suppression. The invention provides a method of repre...
Invention Immunoglobulin expression levels as biomarker for proteasome inhibitor response. Methods of treat...
Invention Dipeptide and tripeptide epoxy ketone protease inhibitors. Provided herein are dipeptide and trip...
Invention Dipeptide and tripeptide epoxy ketone protease inhibitors. 81791268 ABSTRACT Provided herein are ...
2013 Invention Compounds for enzyme inhibition. One aspect of the invention relates to inhibitors that preferen...
Invention Modified release formulations for oprozomib. This disclosure features modified release pharmaceut...
Invention Liposomal compositions of epoxyketone-based proteasome inhibitors. Liposomal compositions compri...
Invention Liposomal compositions of epoxyketone-based proteasome inhibitors. Liposomal compositions compris...
Invention Prodrugs of peptide epoxy ketone protease inhibitors. This disclosure features compounds that ar...
Invention Prodrugs of peptide epoxy ketone protease inhibitors. Provided herein are compounds of formula (I...
Invention Cyclodextrin complexation methods for formulating peptide proteasome inhibitors. This disclosure ...